person with lungs surrounded by elements representing risk factors

Lung cancer in patients who have never smoked

Learn more about this and other topics in our February issue

  • Jaclyn LoPiccolo
  • Alexander Gusev
  • Pasi A. Jänne
Review Article


  • charts overlaid with maps

    In this Collection, you can find the latest articles published in Nature Reviews Clinical Oncology that discuss trends in cancer incidence and mortality.

  • viral particles floating

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic.


    • Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) is a mediator of the cellular replication stress response that, upon activation, initiates a cascade of coordinated reactions that ultimately enables DNA repair. This biological function makes ATR an attractive therapeutic target in cancers with elevated replication stress or DNA-repair deficiency. This Review discusses the currently available results from clinical trials testing ATR inhibitors as well as challenges and solutions in the development of this therapeutic class.

      • Natalie Y. L. Ngoi
      • Patrick G. Pilié
      • Timothy A. Yap
      Review Article
    • Dendritic cells (DCs) are antigen-presenting cells that function at the interface between innate and adaptive immunity, thereby acting as key mediators of antitumour immune responses and immunotherapy efficacy. In this Review, the authors outline the emerging complexity of intratumoural DC states that is being revealed through single-cell analyses as well as the contributions of different DC subsets to anticancer immunity and the activity of immune-checkpoint inhibitors. The authors also discuss advances in the development of DC-based cancer therapies and considerations for their potential combination with other anticancer therapies.

      • Ignacio Heras-Murillo
      • Irene Adán-Barrientos
      • David Sancho
      Review Article
    • Durable responses with first-line platinum-based chemotherapy for advanced-stage urothelial carcinoma are rare, and patient outcomes are poor. Recently, CheckMate 901 became the first phase III trial to establish a significant overall survival benefit from a combined chemoimmunotherapy approach in this disease setting. Herein, we discuss key findings from CheckMate 901 and their implications in the context of a rapidly evolving treatment landscape.

      • Nimira Alimohamed
      • Srikala S. Sridhar
      News & Views
    • Various BRAF alterations are found and function as oncogenic drivers across diverse cancer types. BRAF inhibitor-based therapy has improved outcomes for patients with cancers harbouring BRAFV600 mutations, although resistance develops in most, and the current inhibitors are not effective against other types of BRAF alterations. In this Review, the authors describe the mechanisms underlying oncogenic BRAF signalling, as well as pan-cancer and lineage-specific mechanisms of intrinsic, adaptive and acquired resistance to BRAF inhibitors. They also discuss novel RAF inhibitors and drug combinations designed to overcome these resistance mechanisms and/or expand the applicability of molecularly targeted therapy to a broader range of BRAF-mutant cancers.

      • Aphrothiti J. Hanrahan
      • Ziyu Chen
      • David B. Solit
      Review Article
    • Several novel personalized therapies focus on targeting neoantigens. Such strategies require the identification of suitable vaccine neoepitopes or neoantigen-specific T cell receptor (TCR) clonotypes. Herein, we discuss a recently published report that describes a combined transcriptional and phenotype signature, NeoTCRPBL, that enables the minimally invasive identification of rare neoantigen-specific TCRs from peripheral blood that might enable more-effective T cell-based therapies against cancer.

      • Marco Donia
      • Inge Marie Svane
      News & Views

Nature Careers

Science jobs